-
Mashup Score: 0Cancer Vaccine Likely ‘Several Years’ Away From Wide Availability - 3 month(s) ago
ELI-002, a vaccine for the postsurgical treatment of KRAS-mutated pancreatic and colorectal cancers, is showing promising early study results — but potential commercial availability of the drug is likely several years away as one researcher tells CURE®.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 0Cancer Vaccine Likely ‘Several Years’ Away From Wide Availability - 3 month(s) ago
ELI-002, a vaccine for the postsurgical treatment of KRAS-mutated pancreatic and colorectal cancers, is showing promising early study results — but potential commercial availability of the drug is likely several years away as one researcher tells CURE®.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
A #Cancer #Vaccine for patients with pancreatic and colorectal cancers may be coming soon, but it may still take several years, a researcher said. Watch to Learn More: https://t.co/37l21L3k6b
-
-
Mashup Score: 3First Patient Dosed in Phase 2 Cancer Vaccine Trial - 3 month(s) ago
A phase 2 trial is evaluating ELI-002 7P, a novel cancer vaccine, for the treatment of patients with KRAS-mutant pancreatic cancer.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
A patient with KRAS-mutated pancreatic ductal adenocarcinoma received the first dose of ELI-002 7P, a novel #CancerVaccine, in a phase 2 trial. https://t.co/LfqlAUjlfT
-
-
Mashup Score: 0Cancer Vaccine mRNA-4157 Improves Recurrence-Free Survival for Patients With High-Risk Melanoma - 11 month(s) ago
Adjuvant mRA-4157, in combination with pembrolizumab, improved recurrence-free survival, and distant metastasis-free survival, for patients with high-risk melanoma.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Adjuvant mRA-4157, in combination with pembrolizumab, improved recurrence-free survival, and distant metastasis-free survival, for patients with high-risk melanoma. #oncology #nursing #cancervaccine #ASCO23 https://t.co/RdiflmTUHI
-
-
Mashup Score: 2Cancer Vaccine mRNA-4157 Improves Recurrence-Free Survival for Patients With High-Risk Melanoma - 11 month(s) ago
Adjuvant mRA-4157, in combination with pembrolizumab, improved recurrence-free survival, and distant metastasis-free survival, for patients with high-risk melanoma.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Cancer Vaccine mRNA-4157 Improves Recurrence-Free Survival for Patients With High-Risk Melanoma #oncology #nursing #cancervaccine #ASCO23 https://t.co/NHrzyT5l1a
-
-
Mashup Score: 5Therapeutic and Preventative Cancer Vaccines: The Last 30 Years - 11 month(s) ago
The NCI Division of Cancer Prevention Immunology Interest Group (DCP IIG) is pleased to announce the launch of a new seminar series focused on cancer prevention, interception, and immuno-oncology. Please join us for the upcoming inaugural seminar. Speaker The inaugural speaker is Dr. Olivera (Olja) Finn, University of Pittsburgh Distinguished Professor of Immunology and Surgery and Founding Chair…
Source: prevention.cancer.govCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
We are excited to announce a new @NCIPrevention webinar series. The inaugural seminar, “Therapeutic and Preventative Cancer Vaccines: The Last 30 Years,” will take place on Wed., June 7, 3-4 p.m. ET. Register today. https://t.co/fmRIhv7eMJ #CancerPrevention #CancerVaccine
-
-
Mashup Score: 13Comparing mRNA Vaccines for Treating HPV-Related Cancers - 12 month(s) ago
Three formulations of mRNA vaccines to treat cancers caused by HPV infections, such as cervical and head and neck cancers, showed promise in tests in mice.
Source: National Cancer InstituteCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Three formulations of an #mRNA vaccine designed to treat cancers caused by human papillomavirus (#HPV) infections have been compared in a new study. All three vaccines showed promise in mice. https://t.co/1TRz77zBeQ #CancerVaccine
-
-
Mashup Score: 0Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study - 12 month(s) ago
Objective To quantify the effect on cervical disease at age 20 years of immunisation with bivalent human papillomavirus (HPV) vaccine at age 12-13 years. Design Retrospective population study, 1988-96. Setting National vaccination and cervical screening programmes in Scotland. Participants 138 692 women born between 1 January 1988 and 5 June 1996 and who had a smear test result recorded at age…
Source: The BMJCategories: Latest Headlines, Oncologists2Tweet-
Prevalence of cervical disease at age 20 after immunisation - anti HPV vaccination in children stops people getting cervical cancer - simples ! Anti vax has a lot to answer for #vaccination #cancervaccine #cervicalcancer https://t.co/texybXDILz
-
-
Mashup Score: 1Ohio woman, the first person to receive a breast cancer vaccine in trial, awaits results: 'Very excited' - 1 year(s) ago
An Ohio woman was the first person to get a breast cancer vaccine in 2021. The vaccine could be available to the general public within four to five years, researchers say.
Source: Fox NewsCategories: Hem/Oncs, Latest HeadlinesTweet-
I'd like to hear more about this! Ohio woman, the first person to receive a breast cancer vaccine in trial, awaits results: 'Very excited' @FoxNews https://t.co/kb2qpMOT6c #cancervaccine #breastcancer
-
-
Mashup Score: 0The evidence on the use of a 'Cancer Vaccine’ is encouraging - 1 year(s) ago
The day when the two RNA-based anti-covid-19 vaccines, Pfizer and Moderna, were authorized for use was an important moment for us all. Messenger RNA (mRNA) carries information for the construction of proteins in cells. A major obstacle to overcome in designing an RNA-based vaccine is the limitation is mRNA’s extreme instability. mRNA tends to degrade quickly (unlike DNA, which is a nucleic acid…
Source: Dr. Antonio GiordanoCategories: Hem/Oncs, Latest HeadlinesTweet-
#BlogPost: “The evidence on the use of a 'Cancer Vaccine’ is encouraging” Follow this link to read: https://t.co/6lvsjwjfns #SHRO #cancervaccine #healthcare #cancercare
-
A #Cancer #Vaccine for patients with pancreatic and colorectal cancers may be coming soon, but it may still take several years, a researcher said. Watch to Learn More: https://t.co/37l21L3k6b